Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04432454
Title Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Sermonix Pharmaceuticals Inc.

Her2-receptor negative breast cancer


Abemaciclib + Lasofoxifene

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST